- ASSISTANT PROFESSOR Genetics and Genomic Sciences
PhD, University of Rome
Molecular and Cellular Biology
- Olga Camacho-Vanegas, Ph.D.
Department of Genetics and Genomic Sciences
The Mount Sinai School of Medicine
1425 Madison Avenue , Room 14-26D
New York, New York 10029-6574
ResearchOur Laboratory involve in a number of translational research projects. In particular we are focused on human gene discovery projects with a particular interest in tumor suppressor genes, the generation of animal model for understanding the biological role of these genes in cancer and ultimately the generation of novel therapeutic targets to cure cancer.
Among the projects running in our laboratory, I am leading the project: Linkage analysis and gene descovery for a novel bone dysplasia/cancer syndrome linked to chromosome 9p21-22:DMS-MFH (Diaphyseal medullary stenosis (sclerosis) with bone malignancy (malignant fibrous histiocytoma): Hardcastle syndrome, Malignant fibromatosis)". Throught linkage analysis, we have narrow the disease region to 1.6 Mb and have a identified a very interesting candidate gene. At present, we are in the process to demostrate the discovery a "new tumor suppressor gene". The use of in vivo and in vitro experimental strategies will help us to establish the function of the novel gene and to define the underlying disease mechanisms.
Another project in which I am actively participating is aimed to define the role and the molecular mechanisms by which of the Kruppel-like factor (KLF6) tumor suppressor gene and its KLF6-SV1 splice variant in human cancer.
Difeo A, Narla G, Camacho-Vanegas O, Nishio H, Martignetti JA, Buller RE, Friedman SL, Walsh MJ, Rose SL. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 2006 May 15;.
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Martignetti JA, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Kalir T. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12: 3730-3739.
Goutham N, Difeo A, Yao S, Banno A, Hod E, Reeves HL, Martignetti J, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Qiao RF. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, supresses prostate cancer cell growth and spread. Cancer Research 2005; 65: 5761-5768.
Lucioli S, Pepe G, Mercuri E, Camacho-Vanegas O, Lucarini L, Pietroni V, Urtizberea A, Ben Yaou R, De Visser M, Bonnemann C, Lannaccone ST, Merlini L, Bushby K, Muntoni F, Bertini E, Chu ML, Giusti B. Detection of common and private mutations in the COL6A1 gene of Bethlem myopathy patients. Neurology 2005; 64: 1931-1937.
Vanegas OC, Zhang RZ, Sabatelli P, Lattanzi G, Pepe G, Guisti B, Columbaro M, Chu ML, Merlini L, Bencivenga P. Novel COL6A1 splicing mutation in a family affected by mild Bethlem myopathy. Muscle Nerve 2002; 25: 513-519.
Longo L, Vanegas OC, Patel M, Rosti V, Li H, ande Luzzato L, Merghoub T, Pandolfi PP, Notaro R, Manova K, Waka J. Maternally transmitted severe glucose 6-phospate dehydrogenase deficiency is an embryonic lethal. EMBO J 2002; 21: 4229-4239.
Camacho-Vanegas O, Bertini E, Zhang RZ, Petrini S, Pepe G, Sabatelli P, Giusti B, Chu ML, Minosse C. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc. Natl. Acad. Sci. USA 2001; 98: 7516-7521.
Rovira A, De Angioletti M, Camacho-Vanegas O, Liu D, Luzzatto L, Gallartdo HF, Notaro R, Sadelain R, Rosti V. Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. Blood 2000; 96: 411-417.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Camacho-Vanegas did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 14 Room Lab 14-26
1425 Madison Avenue
New York, NY 10029